JP2020040992A - ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 - Google Patents
ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 Download PDFInfo
- Publication number
- JP2020040992A JP2020040992A JP2019226638A JP2019226638A JP2020040992A JP 2020040992 A JP2020040992 A JP 2020040992A JP 2019226638 A JP2019226638 A JP 2019226638A JP 2019226638 A JP2019226638 A JP 2019226638A JP 2020040992 A JP2020040992 A JP 2020040992A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- neuroendocrine
- cancer
- certain embodiments
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
[該当なし]
本発明は、ソマトスタチン受容体を過剰発現するがんを処置する方法に関する。より具体的には、本発明は、ペプチド受容体放射性核種療法(PRRT)および免疫腫瘍学療法(I−O療法)の組合せが、神経内分泌腫瘍を処置するために投与される併用療法を提供する。
本発明は、例えば、以下の項目を提供する。
(項目1)
ソマトスタチン受容体を過剰発現するがんを有する患者を処置する方法であって、前記患者に、ペプチド受容体放射性核種療法(PRRT)および免疫腫瘍学療法の組合せを投与することを含み、前記PRRTおよび前記免疫腫瘍学療法の複合効果により、前記がんに対する治療効果が生じる、方法。
(項目2)
ソマトスタチン受容体を過剰発現するがんを有する患者を処置する方法であって、前記患者に、ペプチド受容体放射性核種療法(PRRT)およびPD−1/PD−L1/CTLA−4経路を阻害する阻害剤の組合せを投与することを含み、前記PRRTおよびPD−1/PD−L1経路の前記阻害剤の複合効果により、前記がんに対する治療効果が生じる、方法。
(項目3)
前記PRRTが、[177]ルテチウム−DOTA[O]−Tyr[3]−オクトレオテートである、項目1に記載の方法。
(項目4)
前記PD−1/PD−L1/CTLA−4経路の前記阻害剤が、PD−L1を標的とする抗体である、項目1に記載の方法。
(項目5)
前記PD−1/PD−L1経路の前記阻害剤が、PD−1を標的とする抗体である、項目1に記載の方法。
(項目6)
前記PD−1/PD−L1経路の前記阻害剤が、ニボルマブ、MK−3475、MPDL3280A、MED14736、イピリムマブ、およびトレメリムマブからなる群から選択される、項目1に記載の方法。
(項目7)
前記がんが、神経内分泌腫瘍である、項目1に記載の方法。
(項目8)
前記処置が、神経内分泌腫瘍の成長の阻害、神経内分泌腫瘍細胞の増殖の阻害、神経内分泌腫瘍転移の阻害、神経内分泌腫瘍細胞分化の誘導、神経内分泌腫瘍細胞の腫瘍形成能の低減、および神経内分泌腫瘍内のがん幹細胞または腫瘍開始細胞の頻度を低減する方法のうちの1つまたは複数を含む、項目6に記載の方法。
(項目9)
前記神経内分泌腫瘍が、胃腸膵臓神経内分泌腫瘍、カルチノイド腫瘍、褐色細胞腫、傍神経節腫、髄様甲状腺がん、肺神経内分泌腫瘍、胸腺神経内分泌腫瘍、カルチノイド腫瘍または膵神経内分泌腫瘍、下垂体腺腫、副腎腫瘍、メルケル細胞癌、乳がん、非ホジキンリンパ腫、ホジキンリンパ腫、頭頚部腫瘍、尿路上皮癌(膀胱)、腎細胞癌、肝細胞癌、GIST、神経芽細胞腫、胆管腫瘍、子宮頸腫瘍、ユーイング肉腫、骨肉腫、SCLC、前立腺がん、黒色腫、髄膜腫、神経膠腫、髄芽腫 血管芽腫、テント上原始、神経外胚葉性腫瘍、および鼻腔神経芽細胞腫からなる群から選択される、項目6に記載の方法。
(項目10)
前記神経内分泌腫瘍が、機能性カルチノイド腫瘍、膵島細胞腺腫、ガストリノーマ、血管作用性腸管ペプチド(VIP)腫瘍、グルカゴノーマ、セロトニノーマ、ヒスタミン腫瘍、ACTH腫、褐色細胞腫、およびソマトスタチノーマからなる群から選択される、項目6に記載の方法。
(項目11)
前記神経内分泌腫瘍が、低グレード、中グレード、または高グレード神経内分泌腫瘍である、項目6に記載の方法。
(項目12)
前記がんが、小細胞肺がんである、項目1に記載の方法。
(項目13)
前記がんが、進行性中腸神経内分泌腫瘍である、項目1に記載の方法。
(項目14)
前記がんが、サンドスタチン(Novartis)またはSomatuline(登録商標)(Ipsen)に応答性でない、項目12に記載の方法。
(項目15)
前記がんが、PD−1/PD−L1経路の阻害剤に非応答性であるか、または低応答を有する、項目1に記載の方法。
(項目16)
前記神経内分泌腫瘍が、機能性神経内分泌腫瘍である、項目6に記載の方法。
(項目17)
前記神経内分泌腫瘍が、非機能性神経内分泌腫瘍である、項目6に記載の方法。
上記を考慮すると、ルタセラを、PD−1/PD−L1/CTLA−4経路を阻害する阻害剤と組み合わせると、伝統的に処置するのが困難であったNETの有効で新しい処置をもたらすことになることが予想される。
研究により、アミノ酸の静脈内投与は、腎臓保護効果を有することが示された。アミノ酸(リシンおよびアルギニンを含有する)の注入は、177Lu−DOTATATEを投与する30〜45分前に行うことができ、3〜4時間続き得る。
参考文献
Claims (1)
- 明細書に記載の発明。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022174286A JP2023002792A (ja) | 2015-06-25 | 2022-10-31 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562176901P | 2015-06-25 | 2015-06-25 | |
US62/176,901 | 2015-06-25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017567306A Division JP2018518526A (ja) | 2015-06-25 | 2016-06-24 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022174286A Division JP2023002792A (ja) | 2015-06-25 | 2022-10-31 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020040992A true JP2020040992A (ja) | 2020-03-19 |
Family
ID=56940095
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017567306A Pending JP2018518526A (ja) | 2015-06-25 | 2016-06-24 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
JP2019226638A Pending JP2020040992A (ja) | 2015-06-25 | 2019-12-16 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
JP2022174286A Pending JP2023002792A (ja) | 2015-06-25 | 2022-10-31 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017567306A Pending JP2018518526A (ja) | 2015-06-25 | 2016-06-24 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022174286A Pending JP2023002792A (ja) | 2015-06-25 | 2022-10-31 | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20180185524A1 (ja) |
EP (2) | EP3313888A1 (ja) |
JP (3) | JP2018518526A (ja) |
KR (1) | KR20180041623A (ja) |
CN (1) | CN108137690A (ja) |
CA (1) | CA2989266A1 (ja) |
CO (1) | CO2017013041A2 (ja) |
HK (1) | HK1254404A1 (ja) |
IL (1) | IL256543B (ja) |
MX (1) | MX2017016863A (ja) |
SG (1) | SG10201913964QA (ja) |
WO (1) | WO2016207732A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11633506B2 (en) | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
JP2021502368A (ja) * | 2017-11-10 | 2021-01-28 | ウイスコンシン アラムナイ リサーチ ファウンデーシヨンWisconsin Alumni Research Foundation | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法(trt)の使用 |
US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
US10596278B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
CN112955188A (zh) * | 2018-07-25 | 2021-06-11 | 先进加速器应用公司 | 治疗神经内分泌肿瘤的方法 |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
CN113194944A (zh) * | 2018-12-20 | 2021-07-30 | 科塞普特治疗公司 | 用于对生长抑素受体阳性肿瘤进行成像和治疗的方法 |
EP3693974A1 (en) * | 2019-02-07 | 2020-08-12 | Koninklijke Philips N.V. | Identifying responsiveness to radio-immuno combination therapy |
CN113616818B (zh) * | 2020-05-06 | 2023-04-25 | 北京大学 | 一种用于肿瘤的靶向放射与免疫联合治疗的药物组合物 |
CN113248612A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗神经内分泌瘤中的用途 |
CN114401749B (zh) * | 2020-06-29 | 2024-04-16 | 北京拓界生物医药科技有限公司 | 一种放射性核素标记物及其应用 |
CN111840585B (zh) * | 2020-07-20 | 2022-05-03 | 厦门大学 | 一种用于肿瘤免疫治疗的药物组合 |
AU2021330382A1 (en) * | 2020-08-27 | 2023-05-04 | Centre for Probe Development and Commercialization (CPDC) | Radiopharmaceutical and methods |
US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
IL312249A (en) | 2021-11-12 | 2024-06-01 | Advanced Accelerator Applications | Combined treatment for lung cancer |
WO2023208341A1 (en) | 2022-04-27 | 2023-11-02 | ITM Isotope Technologies Munich SE | Combination treatment of small-cell lung cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012533619A (ja) * | 2009-07-20 | 2012-12-27 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830431A (en) | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
NZ701539A (en) * | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
CN104491890A (zh) * | 2014-11-21 | 2015-04-08 | 北京肿瘤医院 | 放射性核素标记的新型生长抑素类似物分子探针及其应用 |
-
2016
- 2016-06-24 CN CN201680048940.5A patent/CN108137690A/zh active Pending
- 2016-06-24 SG SG10201913964QA patent/SG10201913964QA/en unknown
- 2016-06-24 CA CA2989266A patent/CA2989266A1/en active Pending
- 2016-06-24 MX MX2017016863A patent/MX2017016863A/es unknown
- 2016-06-24 US US15/739,234 patent/US20180185524A1/en not_active Abandoned
- 2016-06-24 EP EP16766600.7A patent/EP3313888A1/en not_active Withdrawn
- 2016-06-24 JP JP2017567306A patent/JP2018518526A/ja active Pending
- 2016-06-24 KR KR1020177037167A patent/KR20180041623A/ko not_active Application Discontinuation
- 2016-06-24 WO PCT/IB2016/001089 patent/WO2016207732A1/en active Application Filing
- 2016-06-24 EP EP23203339.9A patent/EP4286008A3/en active Pending
-
2017
- 2017-12-19 CO CONC2017/0013041A patent/CO2017013041A2/es unknown
- 2017-12-25 IL IL256543A patent/IL256543B/en unknown
-
2018
- 2018-10-22 HK HK18113483.7A patent/HK1254404A1/zh unknown
-
2019
- 2019-12-16 JP JP2019226638A patent/JP2020040992A/ja active Pending
-
2022
- 2022-01-20 US US17/579,909 patent/US20220143227A1/en active Pending
- 2022-10-31 JP JP2022174286A patent/JP2023002792A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012533619A (ja) * | 2009-07-20 | 2012-12-27 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ |
Non-Patent Citations (3)
Title |
---|
EUROPEAN JOURNAL OF CANCER, JAN 2015, 51, 421-426, JPN6018045998, ISSN: 0004637904 * |
INT J CLIN EXP PATHOL, 2014, 7(11),7610−7621, JPN6018045999, ISSN: 0004637903 * |
INT. J. ENDO. ONCOL., MAY 2015, 2(2), 151-158, JPN6018045997, ISSN: 0004637902 * |
Also Published As
Publication number | Publication date |
---|---|
EP4286008A3 (en) | 2024-02-28 |
US20220143227A1 (en) | 2022-05-12 |
JP2023002792A (ja) | 2023-01-10 |
IL256543B (en) | 2022-01-01 |
KR20180041623A (ko) | 2018-04-24 |
IL256543A (en) | 2018-02-28 |
EP4286008A2 (en) | 2023-12-06 |
CN108137690A (zh) | 2018-06-08 |
EP3313888A1 (en) | 2018-05-02 |
HK1254404A1 (zh) | 2019-07-19 |
CA2989266A1 (en) | 2016-12-29 |
SG10201913964QA (en) | 2020-03-30 |
CO2017013041A2 (es) | 2018-03-28 |
US20180185524A1 (en) | 2018-07-05 |
WO2016207732A1 (en) | 2016-12-29 |
JP2018518526A (ja) | 2018-07-12 |
MX2017016863A (es) | 2018-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020040992A (ja) | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 | |
JP6464085B2 (ja) | 神経膠芽腫の治療のための併用療法 | |
JP7482180B2 (ja) | 癌のための併用療法 | |
KR102417583B1 (ko) | Her2-양성 유방암 어쥬번트 치료 | |
Alme et al. | Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview | |
JP7234303B2 (ja) | 進行したher2発現がんの治療 | |
JP2024059699A (ja) | Iapアンタゴニスト及び抗pd-1分子による併用抗癌療法 | |
Philippou et al. | Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer | |
KR20210084560A (ko) | Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제 | |
EP4090431A1 (en) | Methods and compositions for cancer immunotherapy | |
WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
US20230302168A1 (en) | Dr5 radioimmunotherapy in the treatment of solid cancers | |
WO2019070497A1 (en) | POLY THERAPY AGAINST CANCER | |
US20210113692A1 (en) | Dosing regimen | |
WO2022226637A1 (en) | Method for allowing immune cells infiltration in tumors | |
WO2022248268A1 (en) | Combination therapy | |
Li et al. | Monoclonal antibody therapy in Non-Small Cell Lung Cancer | |
WO2018035210A1 (en) | Methods and monitoring of treatment with an rspo antagonist | |
Hewish et al. | Insulin-Like Growth Factor Receptor Inhibitors: Categorical Lack of Efficacy or Lack of Personalised Medicine? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220412 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220630 |